Hyogo Prefectural Harima-Himeji General Medical Center, Japan.
National Hospital Organization, Hakodate National Hospital, Japan.
Intern Med. 2023 Feb 15;62(4):495-502. doi: 10.2169/internalmedicine.9646-22. Epub 2022 Jul 29.
Objective To evaluate the efficacy and safety of rabeprazole coadministration with low-dose aspirin (LDA). Methods From 2015 to 2018, we conducted a large-scale, multicenter, prospective observational study to assess the safety and efficacy of treatment with rabeprazole (5 or 10 mg/day) in combination with LDA. Results The incidence of adverse reactions was 0.73% (11/1,513 patients), with no serious adverse reactions. We found no trend toward increases in the incidence of adverse reactions with increases in treatment duration. The cumulative recurrence rate of ulcers by Week 52 (Kaplan-Meier estimates) was 3.50% (range, 1.56-7.75%). No gastrointestinal bleeding was reported. Conclusion Rabeprazole in combination with LDA appears as safe and effective in real-world situations as in clinical trials.
目的 评估雷贝拉唑与低剂量阿司匹林（LDA）合用的疗效和安全性。
方法 2015 年至 2018 年，我们开展了一项大规模、多中心、前瞻性观察性研究，以评估雷贝拉唑（5 或 10 mg/天）联合 LDA 治疗的安全性和疗效。
结果 不良反应发生率为 0.73%（11/1513 例患者），无严重不良反应。我们发现不良反应发生率与治疗时间的延长无明显增加趋势。第 52 周（Kaplan-Meier 估计）溃疡的累积复发率为 3.50%（范围为 1.56-7.75%）。未报告胃肠道出血。
结论 雷贝拉唑联合 LDA 在真实世界中的安全性和疗效与临床试验相当。
